Protalix Biotherapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on July 13, 2023, by Protalix Biotherapeutics, Inc. (PLX), a Delaware corporation. The report details the results of the reconvened 2023 Annual Meeting of Stockholders, which was initially scheduled for June 28, 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
Stockholders approved an amendment to the Company's Certificate of Incorporation to increase the number of authorized common shares. The authorized share count was raised from 144,000,000 to 185,000,000 shares, with a par value of $0.001 per share.
Voting Results
| Vote Category | Number of Votes |
|---|---|
| For | 33,870,055 |
| Against | 9,479,063 |
| Abstain | 1,042,433 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the disclosure of the stockholder vote outcome.
Key Facts for Investors to Verify
- Confirmation that the amendment to the Certificate of Incorporation has been filed with the State of Delaware to become effective.
- Assessment of the impact of the increased authorized share count (from 144 million to 185 million) on potential future dilution.
- Review of the Company's most recent 10-Q or 10-K for current financial health, as this 8-K contains no financial metrics.